<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681263</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.213</org_study_id>
    <secondary_id>2015-004178-14</secondary_id>
    <nct_id>NCT02681263</nct_id>
  </id_info>
  <brief_title>Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae</brief_title>
  <acronym>TEMO-ESBL</acronym>
  <official_title>Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French National Network of Clinical Research in Infectious Diseases (RENARCI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at demonstrating the efficacy of temocillin in the treatment of UTI
      requiring parenteral therapy due to a confirmed ESBL producing or AmpC hyperproducing
      Enterobacteriaceae, resistant to quinolones and Bactrim® in France. In addition, this study
      will describe and support the use of high dose (6g/day) of temocillin which could be of
      interest for the treatment urinary tract infection due to multi-resistant bacteria having
      high MIC (up to 32 mg/L). The investigators will also evaluate the tolerance of the drug by
      monitoring the adverse event and the incidence of eventual Clostridium difficile associated
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological efficacy at Test of Cure in patients microbiologically evaluable</measure>
    <time_frame>7 days post end of Temocillin Treatment</time_frame>
    <description>The microbiological efficacy will be assessed by quantitative urine culture and defined as follows:
Eradication : &lt; 10^3 CFU/mL of the baseline pathogen
Persistence : ≥ 10^3 CFU/ml of the baseline pathogen
Superinfection : ≥ 10^5 CFU/ml of another uropathogen during therapy
New infection : ≥ 10^5 CFU/ml of another uropathogen after therapy
Relapse : eradication at TOC but ≥ 10^3 CFU/mL of the baseline pathogen at FU Overall microbiological response will be determined as &quot;unfavorable&quot; if persistence or superinfection or new infection or relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy in clinical evaluable group</measure>
    <time_frame>3 weeks for end of Temocillin Treatment</time_frame>
    <description>Each patient's response will be categorized as cure (resolution of all clinical symptoms), improvement (normalization of body temperature but persistence of either urinary syndrome or flank pain) or failure (persistence of baseline clinical symptoms or emergence of new symptoms related to UTI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological efficacy</measure>
    <time_frame>3 weeks for end of Temocillin Treatment</time_frame>
    <description>The microbiological efficacy will be assessed by quantitative urine culture and defined as follows:
Eradication : &lt; 10^3 CFU/mL of the baseline pathogen
Persistence : ≥ 10^3 CFU/ml of the baseline pathogen
Superinfection : ≥ 10^5 CFU/ml of another uropathogen during therapy
New infection : ≥ 10^5 CFU/ml of another uropathogen after therapy
Relapse : eradication at TOC but ≥ 10^3 CFU/mL of the baseline pathogen at FU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of resistance to temocillin during treatment</measure>
    <time_frame>3 weeks for end of Temocillin Treatment</time_frame>
    <description>The acquisition of resistance will be monitored in the central laboratory and is defined as an increase in MIC of at least 4 dilutions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Temocillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temocillin</intervention_name>
    <description>Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.</description>
    <arm_group_label>Temocillin</arm_group_label>
    <other_name>NEGABAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of at least 18 year old

          -  Patient benefits from social security

          -  Signed informed consent

          -  A urinary tract infection due to a confirmed ESBL producing strain (detected by the
             use of a rapid diagnostic test applied on the urine) requiring parenteral
             antimicrobial therapy

          -  Hospitalized patient

          -  For women able to procreate: Use of an acceptable method of birth control throughout
             the study. Acceptable methods of birth control are: oral contraceptives, intrauterine
             device (IUD), diaphragm with spermicide and condom. (All forms of hormonal
             contraception are acceptable

        Exclusion Criteria:

          -  Patient infected with a bacteria which is not an ESBL-producing or AmpC hyperproducing
             Enterobacteriaceae

          -  Patients infected with a strain sensible to both fluoroquinolones and
             trimethoprim/sulfamethoxazole

          -  Patients infected with a strain resistant to temocillin

          -  Hospital-acquired urinary tract infection (defined as a urinary infection that
             occurred at least 48h post admission in the hospital)

          -  Patients has received any dose of active antimicrobial therapy (an antibiotic to which
             the infecting bacterium is susceptible) in the last 48h (prior to enrolment) except ≤
             2 dose of gentamicin.

          -  Patients presenting another site of infection than urinary (except onset of
             bacteraemia from urinary tract origin) due to Gram negative bacteria.

          -  Patients needing concomitant antimicrobial therapy.

          -  Septic shock

          -  Children (up to 18 years old)

          -  Women who is pregnant, breastfeeding, or expecting to conceive at any time during the
             study (pregnancy test will be conducted for woman without menopause)

          -  Patients with any kind of urinary/bladder catheter (JJ ureteral probe, …)

          -  Hypersensitivity to the active substance, to penicillins or to any other type of
             beta-lactam agent

          -  Chronically dialyzed patients

          -  Patients having a creatinine clearance &lt; 30 mL/min

          -  Complete obstruction of the urinary tract

          -  Perinephretic or intrarenal abscesses

          -  Tutorship or curatorship patient

          -  Patient unable to give his consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Paul STAHL, PU-PH</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion NORET, MSc.</last_name>
    <phone>+33 1 71 20 70 25</phone>
    <email>marion.noret@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Ajaccio</name>
      <address>
        <city>Ajaccio</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernard CASTAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie PIET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric MECHAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Beaujon Hospital</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victoire DELASTOUR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Fort de France</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>André CABIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Paul STAHL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Bicêtre Hospital</name>
      <address>
        <city>Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin WPLOSZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tatiana GALPERINE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David BOUTOILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Véronique MONDAIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xavier LESCURE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rémy Gauzit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Matthieu LAFAURIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hugues AUMAITRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Pointe à Pitre</name>
      <address>
        <city>Pointe à Pitre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kinda SCHEPERS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>France CAZENAVE - ROBLOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel ETIENNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric LUCHT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Louis BERNARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Laterre PF, Wittebole X, Van de Velde S, Muller AE, Mouton JW, Carryn S, Tulkens PM, Dugernier T. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother. 2015 Mar;70(3):891-8. doi: 10.1093/jac/dku465. Epub 2014 Nov 27.</citation>
    <PMID>25433006</PMID>
  </reference>
  <reference>
    <citation>Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, Virgincar N, Iyer S, Carryn S, Van de Velde S. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2011 Nov;66(11):2628-31. doi: 10.1093/jac/dkr317. Epub 2011 Aug 2.</citation>
    <PMID>21810837</PMID>
  </reference>
  <reference>
    <citation>Fournier D, Chirouze C, Leroy J, Cholley P, Talon D, Plésiat P, Bertrand X. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect. 2013 Feb;43(2):62-6. doi: 10.1016/j.medmal.2013.01.006. Epub 2013 Feb 19.</citation>
    <PMID>23433608</PMID>
  </reference>
  <reference>
    <citation>Schulze B, Heilmann HD. Treatment of severe infections with temocillin. Clinical and bacteriological evaluation. Drugs. 1985;29 Suppl 5:207-9.</citation>
    <PMID>4029026</PMID>
  </reference>
  <reference>
    <citation>De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother. 2008 Feb;61(2):382-8. Epub 2007 Dec 10.</citation>
    <PMID>18070831</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temocillin</mesh_term>
    <mesh_term>Penicillins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

